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Summary
Immune thrombocytopenia (ITP) of childhood is characterized by isolated, immune-media-
ted thrombocytopenia. ITP occurs most commonly in young children following a viral infection. 
It is usually a benign disorder with spontaneous recovery within following weeks or months. The 
optimal management including investigations, treatment, and follow-up of children with ITP is a 
matter of debate. Recent guidelines recommend that careful observation is appropriate for pedi-
atric patients with no or mild bleeding regardless of platelet count. Pharmacologic intervention is 
required for children with severe bleeding.
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INTRODUCTION
Childhood immune thrombocytopenia (ITP) is an acquired autoimmune disor-
der characterized by isolated thrombocytopenia (peripheral blood platelet count < 
100 x 109/L). ITP is one of the most common bleeding disorders in children, with an 
incidence of approximately four per 100.000 per year [1,2]. ITP most frequently pre-
sents with acute onset of purpura and bruising in an otherwise healthy child, often 
after a preceding mild viral infection. A benign and self-limited course is common, 
and major bleeding complications are exceptional [1]. The management including 
diagnostic investigations, treatment and follow-up is controversial [3]. This review 
presents the current nomenclature, diagnosis, differential diagnosis, treatment op-
tions, and prognosis of children with ITP.
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Nomenclature
The current nomenclature was proposed by International Working Group 
(IWG) of both pediatric and adult experts in ITP at the Vicenza Consensus Confe-
rence in 2009 [4]. IWG recommended term “immune thrombocytopenia”, instead 
of previous “idiopathic thrombocytopenic purpura” or “immune thrombocytope-
nic purpura”. Current term Immune ThrombocytoPenia preserves its most widely 
accepted abbreviation “ITP”, while underlying the immune-mediated nature of the 
disease. “Purpura” was proposed to be omitted since many patients have no or mi-
nimal bleeding symptoms. ITP in the absence of other causes or disorders known to 
reduce platelet count is known as primary ITP, while secondary ITP is characterized 
by the presence of an underlying disorder, including ITP that is drug-induced. IWG 
defined three different phases of ITP: “newly diagnosed ITP” (ITP within 3 mont-
hs from diagnosis), “persistent ITP” (ongoing ITP between 3 and 12 months from 
diagnosis), and “chronic ITP” (ITP lasting more than 12 months). Severity of ITP is 
based on the presence of bleeding signs rather than the degree of thrombocytope-
nia. The term “severe ITP” should be used only in patients with clinically relevant 
bleeding, which is defined as bleeding at presentation sufficient to mandate trea-
tment, or occurrence of new bleeding symptoms requiring additional therapeutic 
intervention or increase in drug dose. 
Pathophysiology
ITP is an immune-mediated disorder with complex pathophysiology. The key 
element in the pathogenesis is loss of self-tolerance leading to production of auto-
antibodies against platelet membrane antigens, in particular glycoprotein IIb/IIIa 
complex [1]. The antibody-coated platelets have a shortened half-life because of Fc 
receptor-mediated phagocytosis by tissue macrophages, predominantly those in the 
spleen. The same antibodies may inhibit platelet production. In addition to activa-
ted B-cells and increased phagocytic activity, cellular immunity is perturbed, and 
T-cell and cytokine profiles are significantly shifted toward a type 1 and Th17 pro-
inflammatory immune response [5]. Further, a genetic predisposition to ITP likely 
plays a role in susceptibility to developing ITP in specific conditions. This finding is 
supported by rare reports of familial ITP, increased frequency of ITP in some gene-
tic syndromes (common variable immunodeficiency, autoimmune lymphoprolifera-
tive syndrome, and hyper IgM syndrome), and evidence of an association between 
ITP and several candidate immune genes [5, 6]. Various underlying pathophysiolo-
gical immune mechanisms are responsible for the clinical heterogeneity of ITP and 
different response to the treatment.
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Epidemiology
Annual incidence of ITP is estimated to be between 1.9 and 6.4 cases per 100.000 
children. This rate is probably an underestimate because it is based primarily on 
symptomatic and hospitalized patients [7]. Children with ITP can present at any 
age, but there is a peak between two and five years and a smaller peak in adolescen-
ce. There is a slight predominance of boys to girls, especially in infants. In a large 
study of the Intercontinental Childhood ITP Study Group (ICIS) that included 2540 
pediatric patients, the mean age at presentation was 5.7 years. Seventy percent of 
children were between 1 and 10 years old, 10% were infants (older than 3 and less 
than 12 months old), and the remaining 20% were older (ages 10 to 16 years). Boys 
and girls were affected approximately equally. In infants, the male to female ratio 
was 1.7:1. The male predominance was minimal in older children, such that the 
overall male to female ratio in this study was 1.2:1 [8]. Seasonal occurrence has been 
reported, with the highest incidence in the spring and lowest in the autumn, most 
probably reflecting seasonal variations in viral illnesses. 
Clinical manifestations
ITP in children typically presents with the sudden onset of a purpura or bruising 
in an otherwise healthy child. In almost two thirds of pediatric patients, there is a hi-
story of a prior viral infection, mainly an upper respiratory tract infection. The interval 
between the preceding infection and the onset of purpura varies from a few days to se-
veral weeks, with the most frequent interval about two weeks. In a minority of children, 
ITP occurs following MMR (measles, mumps and rubella) vaccination. MMR-associa-
ted ITP occurs rarely, in one to three cases per 100.000 doses of vaccine [2,9]. 
Approximately 60% of children with ITP have only skin bleeding at presenta-
tion that include petechial or purpuric rash or bruising, also referred to as “dry 
purpura”. Mucosal bleeding (“wet purpura”) may be present in as many as 40% of 
children with ITP. It involves epistaxis, buccal and gingival bleeding, and, much 
less frequently, hematuria, menorrhagia, or gastrointestinal bleeding. Other than 
the evidence of mucocutaneous bleeding, patients appear well and have no systemic 
symptoms such as fever, weight loss, or bone/joint pain. On physical examinati-
on, no significant lymphadenopathy or hepatosplenomegaly is present; if present, 
another diagnosis should be strongly considered. However, small cervical adeno-
pathy is common in young children, and slightly palpable spleen may be present in 
5% to 10% of children with ITP [10,11]. 
Severe hemorrhage requiring hospital admission and/or blood transfusions is 
rare, and occurs in about 3% of children with ITP (12). The most feared complication 
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of ITP is intracranial hemorrhage (ICH). The incidence of ICH is 0.1 to 0.8%, and is 
even lower in children with persistent thrombocytopenia. Patients with ICH and 
ITP are more likely to have a history of head trauma and wet purpura; in the majo-
rity of patients platelet count is less than 10 x 109/L [1,13]. 
Several attempts have been undertaken to establish a scoring system assessing 
the extent of bleeding in order to standardize treatment decisions and monitor the 
platelet response. Bolton-Meggs and Moon arbitrarily divided bleeding signs into 
four categories: none, mild, moderate, and severe [14]. Buchanan and Adix develo-
ped scoring system allowing semiquantitative assessment of hemorrhage based on 
physical examination and history of new bleeding during the previous 24 hours [15]. 
Edslev and co-workers proposed a clinical score predicting a brief and uneventful 
course of newly diagnosed ITP in children [16]. Pediatric bleeding score tools are 
summarized in Table 1. 
Table 1. Grading and scoring systems in pediatric ITP
Bolton Maggs  
and Moon (14) Buchanan and Adix (15) Edslev and co-workers (16)
Asymptomatic
No symptoms
Mild
Bruising and petechiae; 
occasional minor epistaxis, 
very little or no interference 
with daily living
Moderate
More severe skin 
manifestations with some 
mucosal lesions; more 
troublesome epistaxis and 
menorrhagia
Severe
Bleeding episodes 
(epistaxis, melena and / 
or menorrhagia) requiring 
hospital admission and / or 
blood transfusion; symptoms 
seriously interfering with 
quality of life
Grading of haemorrhage 
in children with ITP based 
upon history prior 24 hours 
and physical examination
Grade 0-5
0 none
1 minor
2 mild
3 moderate
4 severe
5 life-threatening or 
fatal
Skin bleeding (0-4)
Epistaxis (0-4)
Oral bleeding (0-4)
Overall bleeding (0-5)
Scoring system based on 6 
clinical features
Six clinical features with 
prognostic information 
(weight)
Abrupt onset (5)
Age <10 years (3)
Preceding infection (2)
Platelet count <5 x 109 / L (1)
Wet purpura (1)
Male gender (1)
High scores (10–14) identify 
low-risk patients
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Laboratory findings
ITP is characterized by isolated thrombocytopenia. In most reports, presenting 
platelet count is less than 30 x 109/L, probably because patients with mild disease 
may not come to medical attention. About 80% of children with ITP have platelet 
count less than 20 x 109/L, and 44% less than 10 x 109/L [8,17]. Other hematologic ab-
normalities are consistent with the newly diagnosed ITP only if they can be explai-
ned easily, e.g. microcytic anemia in children with significant bleeding, or atypical 
lymphocytes in post-infectious cases. The exception is mild eosinophilia, which is 
a common finding. 
For the typical cases of childhood ITP a complete blood count with a careful exa-
mination of the peripheral blood smear are the only necessary investigations. The 
blood smear shows normal morphology of all cell lines with platelets either normal 
in size or variably sized with some large platelets [1]. Antiplatelet antibodies, de-
tected in 60% to 70% of cases, are not normally helpful as they are of no prognostic 
significance [18]. Besides, there is no evidence to recommend the routine testing of 
other autoimmune antibodies (antinuclear, antiphospholipid, antithyroid), platelet 
parameters (platelet volume, reticulated platelets), or serum thrombopoietin levels 
in the evaluation of children with suspected ITP [19]. The utility of measuring im-
munoglobulins in all patients to exclude common variable immune deficiency is 
equivocal [2]. Bone marrow examination is not routinely performed in children with 
typical ITP. According to the American Society of Hematology (ASH) guidelines, it 
is not necessary in children with typical features of ITP and in those who fail to res-
pond intravenous immunoglobulin (IVIG). Important indications for bone marrow 
aspiration include atypical clinical or laboratory features at presentation that sug-
gest malignancy or bone marrow failure, therapy-refractory ITP, and new findings 
that emerge during follow-up that are inconsistent with ITP [19]. 
Differential diagnosis
Primary ITP in children is a diagnosis of exclusion. The diagnosis of ITP is gen-
erally considered in well-appearing child with spontaneous abrupt onset of muco-
cutaneous bleeding and an isolated, often profound thrombocytopenia. For chil-
dren with laboratory abnormalities other than thrombocytopenia or with atypical 
clinical findings, other conditions that can cause thrombocytopenia must be ruled 
out. The differential diagnosis of thrombocytopenia in pediatric population is very 
broad. It includes pseudothrombocytopenia (EDTA-induced platelet agglutination), 
active infection (e.g. infectious mononucleosis, hepatitis, HIV-1), autoimmune hemo-
lytic anemia (Evans syndrome), systemic autoimmune diseases (e.g. systemic lupus 
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erythematosus, antiphospholipid syndrome), drug exposure (e.g. heparin, quini-
dine, phenytoin, sulfonamides, vancomycin), bone marrow failure syndromes (e.g. 
aplastic anemia, myelodysplastic syndrome), consumptive processes (e.g. hemolytic 
uremic syndrome, thrombotic thrombocytopenic purpura, disseminated intravas-
cular coagulation), immunodeficiency syndromes (e.g. common variable immuno-
deficiency, Wiscott Aldrich syndrome), and inherited thrombocytopenic disorders 
(e.g. inherited aplastic anemia, thrombocytopenia-absent radius syndrome, von 
Willebrand disease type 2B) [10,11]. 
Table 2 lists possible causes of thrombocytopenia, and suggested tests that are 
helpful in distinguishing between disorders. 
Table 2. Differential diagnosis of thrombocytopenia and suggested tests
Condition Disorder Suggested tests
Analytical 
reasons Pseudothrombocytopenia
Peripheral blood smear; 
alternative anticoagulant, e.g., 
heparin or citrate
Acquired
peripheral
destruction
Disseminated intravascular coagulation
Complete blood count, 
peripheral blood smear, 
coagulation tests
Haemolytic uremic syndrome
Thrombotic thrombocytopenic purpura
Post-transfusion purpura
Splenic sequestration
Kassabach-Merrit syndrome
Cardiovascular disease
Neonatal alloimmune 
thrombocytopenia
HPA genotyping: maternal 
platelet antibody investigations
Drug-induced thrombocytopenia Antibodies against drugs
Liver diseases Liver function tests
Infectious diseases Serology (HIV, HBV, HCV, CMV) 
Systemic lupus erythematosus Antinuclear antibodies, direct antiglobulin test
Antiphospholipid autoantibodies Lupus anticoagulant, anticardiolipin
Acquired 
production
failure
Myelodysplastic syndrome Bone marrow aspiration  
and biopsy
Genetic studies
Bone marrow infiltration
Aplastic anaemia
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Inherited
thrombocytopenia
Thrombasthenia Glanzmann
Family history, complete blood 
count, peripheral blood smear 
(platelet morphology and size), 
platelet flow cytometry, bone 
marrow aspiration and biopsy, 
genetic studies
Bernard–Soulier syndrome
Mediterranean thrombocytopenia
Gray platelet syndrome
Paris-Trousseau thrombocytopenia /
Jacobsen syndrome
Velocardiofacial syndrome, 
DiGeorge syndrome
Wiskott–Aldrich syndrome
X-linked thrombocytopenia
Congenital amegakaryocytemia
Thrombocytopenia-absent radius 
syndrome
MYH-9-related disorders
GATA1 mutation
Von Willebrand disease type 2B Von Willebrand factor, multimer analysis, Factor VIII
Fanconi anaemia
Complete blood count, 
peripheral blood smear; 
karyotype/chromosomal 
breakage, genetic studies
Autoimmune lymphoproliferative 
syndrome
Complete blood count, Fas 
protein, Fas ligand
Prognosis
Children with ITP have an excellent chance of recovery with or without trea-
tment. Typically, bleeding signs subside within weeks, and the platelet count re-
turns to normal in a few weeks to months. Overall, 70% to 80% of children diagno-
sed with ITP will go into complete remission within a few months [1]. Remission 
rate of 87%, achieved by watchful waiting without specific therapy 6 months after 
initial presentation, has been reported [20]. In ICIS Registry I involving 2031 su-
bjects, an equal percentage of children had resolved their ITP at 6 months irres-
pective of whether they had been managed by observation only or had received 
platelet enhancing therapy. Moreover, 25% of children with thrombocytopenia la-
sting more than 6 months recovered over the next 6 months [21]. Data from ICIS 
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Registry II involving 1345 children supported that ITP is a benign condition for 
most affected children. Remission occurred in 37% of patients between 28 days and 
6 months after the initial presentation, in 16% between 6 and 12 months, and in 
24% between 12 and 24 months [22]. A recent systematic review and meta-analysis 
identified following predictors of chronic ITP in children: older age, insidious onset, 
no preceding infection or vaccination, mild bleeding, and higher platelet counts at 
presentation (> 20 x 109/L) [23]. Finally, two genetic biomarkers have been suggested 
as predictors of chronic disease: overexpression of vanin-1 (VNN-1), an oxidative 
stress sensor, and the Q63R missense variant of the gene encoding the cannabinoid 
receptor type 2 [24]. 
Management
Management of childhood ITP remains controversial. Besides bleeding mani-
festations and platelet count, pediatric hematologists should consider a number of 
factors when considering treatment decisions, such as age, physical activities, he-
alth-related quality of life, potential co-morbidities and co-medications, duration of 
the disease, geographic distance from a tertiary care center, patient’s and parents 
preferences, time lost from school due to hospital visits, psychosocial impact and 
economic aspects [1,2]. 
In majority of pediatric cases ITP is a benign self-limited disorder that requires 
no or minimal therapy [1,25,26]. Universal supportive measure is the avoidance of 
medications that inhibit platelet function, including non-steroidal anti-inflamma-
tory drugs, aspirin-containing preparations and anticoagulants. There is a great 
variation in how children with ITP are counseled with respect to activity restricti-
ons. Most practitioners advice against participation in any activity associated with 
a significant risk of trauma (especially head injury) when platelet count is less than 
30 x 109/L. For active toddlers and preschool children, protective helmets with close 
supervision are recommended. For older children and adolescents, restrictions often 
involve avoiding contact sports in the period of profound thrombocytopenia [1].
Depending on patient characteristics, appropriate initial management of a child 
with newly diagnosed ITP may be either observation or pharmacologic interventi-
on. There is currently no consensus which therapeutic option is preferably used in 
a given situation.
Watchful waiting
The self-limited nature of childhood ITP and very low incidence of severe blee-
ding is the basis of a non-interventional strategy. Pharmacotherapy has proven to 
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be mostly effective in raising the platelet count in a short period of time, but it has 
never been demonstrated that the fast platelet response is of clinical significance 
[26]. ASH practice guidelines recommend that children with no bleeding or mild 
bleeding (defined as skin manifestations only), be managed with observation alone 
regardless of platelet count [22]. This “watch and see” strategy is now accepted by 
many experts.
Pharmacologic intervention
When platelet-enhancing therapy is indicated, the primary treatment options 
for a child with newly diagnosed ITP include IVIG or corticosteroids. Both of the-
se pharmacologic approaches interfere with antibody-mediated clearance of plate-
lets, and most patients respond within days of administration [1,28]. Selection of 
treatment and dosing/duration varies substantially among care providers. Platelet 
transfusion is generally contraindicated, with the exception of patients with life-
threating hemorrhage or patients requiring urgent surgical procedures.
Corticosteroids
Different protocols of oral glucocorticoids have been used for decades to pati-
ents with ITP of all age groups. The most traditional regimen is oral prednisone in a 
daily dose of 2 mg/kg/day (60 mg maximum) for 2 weeks with tapering over 1 week 
[2]. There are observations that higher doses of steroids (intravenous methylpredni-
solone 30 mg/kg/day for 3 days, or oral methylprednisolone 30 mg/kg/day for 3 days 
followed by 20 mg/kg/d for 4 days) result in faster response, but without clinical 
benefit [29,30]. Data suggest that a short course of oral prednisone with 4 mg/kg/
day for 4 days without tapering is effective and less toxic. Most common side effects 
of corticosteroid therapy include mood changes, sleep disturbance, hypertension, 
weight gain, and gastritis. Oral dexamethasone is not the first-line therapy in chil-
dren, because of the predictable significant adverse events [1,2]. 
Immunoglobulins
IVIG raises the platelet count in more than 80% of children with newly diagno-
sed ITP. An increase in platelet count is usually observed within 24 hours. The ori-
ginal IVIG dose of 0.4 g/kg/day for 5 days has been superseded by shorter courses. 
It is generally administered in a single dose of 0.8 to 1 g/kg, with possible repeated 
treatment based on the short-term platelet response [31]. Transient side effects inclu-
de headache, fever, nausea, and vomiting. 
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Anti-D immunoglobulin
Intravenous anti-D immunoglobulin (anti-D) as a single dose of 50 to 75 μg/
kg can be effectively given to Rh-positive non-splenectomized children with ITP 
requiring treatment. Patients should be monitored for 8 hours after the infusion [1]. 
The use of anti-D as the first-line treatment remains controversial with respect to 
the risk of hemolysis. Besides, it is not currently licensed in European countries [31]. 
Life-threatening bleeding
On very rare occasions, children with ITP present with organ- or life-threate-
ning bleeding. The goal of emergency treatment is to raise rapidly the platelet count 
to a level where the risk of severe bleeding is minimized. International consensus 
2010 report recommends combination of therapies, including platelet transfusions 
(two- to three-fold larger-than-usual doses due to rapid platelet destruction, someti-
mes followed by continuous infusion), high doses of intravenous methylprednisolo-
ne (30 mg/kg over 20 to 30 minutes, maximum 1 g), and IVIG (1 g/kg/day for 2 days) 
[31,32]. Emergent splenectomy should be considered for patients with life-threate-
ning bleeding refractory to medical management [1]. 
Treatment options for children with persistent or chronic ITP
The decision to treat a child who is unresponsive to initial treatment and /or who 
has persistent or chronic ITP should be individualized, relying largely on the frequ-
ency and severity of hemorrhage and the impact on quality of life. If previous tre-
atments with steroids or IVIG have been successful, these drugs may be used as nee-
ded to prevent bleeding. Prolonged use of corticosteroid therapy should be avoided 
because of adverse effects, especially on growth [2]. Other treatments are preferred 
for pediatric patients with unresponsive persistent or chronic ITP and clinically si-
gnificant bleeding. Rituximab (chimeric monoclonal anti-CD20 antibody) has been 
administered in case series, with response rate between 31% and 68% [31]. Several 
dosing regimens have been used, most frequently as a dose 375 mg/m2 for 4 consecu-
tive weeks. It has been demonstrated that response to corticosteroids strongly corre-
lated with the response to rituximab, yet 48% of children unresponsive to steroids 
responded to rituximab [3]. Thrombopoietin-receptor agonists may have a role in the 
treatment of severe chronic ITP in children. Two randomized studies investigating 
romiplostin (given subcutaneously once a week) reported platelet increase in more 
than 80% of children; the response was maintained for a median of 7 weeks. Larger 
studies are needed in children, concerning efficacy and long-term safety. Numero-
us other medications interfering with the immune system have been used in a limi-
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ted number of children. These include azathioprine, cyclosporine A, mycophenolate 
mofetil, danazol, and dapsone. Cytotoxic drugs (cyclophosphamide, vinca alkaloids) 
have been tried in severe refractory ITP, but should be used with extreme caution in 
children [34,35]. 
Splenectomy in children is generally deferred for as long as possible. Current 
guidelines agree that it should be postponed for at least 12 months after the initial 
diagnosis of ITP, due to the possible spontaneous remissions [36]. Although 60% 
to 80% of pediatric patients initially respond to splenectomy, it is associated with 
substantial risk of serious complications especially overwhelming sepsis [1]. ASH 
guidelines recommend splenectomy for children and adolescents with chronic or 
persistent ITP who have significant or persistent bleeding, and lack of responsi-
veness or intolerance of other therapies (corticosteroids, IVIG, and anti-D) and/or 
who have a need for improved quality of life. If elective splenectomy is planned, 
vaccinations against encapsulated bacteria should be completed preoperatively. 
Prophylactic antibiotic therapy (penicillin or alternatives in the case of penicillin 
allergy) is recommended [22,31]. Children with chronic severe ITP who fail to remit 
after splenectomy present very challenging management decisions for pediatric he-
matologists, that should be made in collaboration with the patient and the family.
CONCLUSION
Immune thrombocytopenia in children is a relatively uncommon and generally 
benign self-limited condition presenting as abrupt onset of bleeding tendency in an 
otherwise healthy child. Diagnostic approach includes history, clinical examination 
and full blood count with peripheral blood smear. Indications for treatment have 
not been standardized and include bleeding, quality of life and parental anxiety. 
Observation only should be considered in pediatric patients with mild disease. In-
travenous immunoglobulin and steroids are the current frontline pharmacologic 
approaches for children at risk for severe bleeding.
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Sažetak
Imuna trombocitopenija u djece 
Imuna trombocitopenija (ITP) u djetinjstvu je karakterizirana izoliranom, imunološki posre-
dovanom trombocitopenijom. ITP se najčešće pojavljuje u male djece nakon virusne infekcije. 
U pravilu se radi o benignom poremećaju sa spontanim oporavkom unutar nekoliko tjedana ili 
mjeseci. Optimalan pristup pedijatrijskoj ITP, koji uključuje dijagnostičke postupke, liječenje i 
praćenje, nije usaglašen. Novije smjernice preporučuju pažljivo praćenje pedijatrijskih bolesnika 
s odsutnim ili blagim krvarenjem, bez obzira na broj trombocita. Farmakološko liječenje je indi-
cirano u djece s ozbiljnim krvarenjem. 
Ključne riječi: imuna trombocitopenija, dijete, trombociti
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